What is the primary driver behind the significant decrease in net earnings for the first quarter of 2005?

The significant decrease in net earnings from continuing operations (down 44%) was primarily driven by the absence of a large gain on the sale of the Adult Nutritional business in the prior year ($295 million in Q1 2004) and a substantial increase in litigation charges ($124 million in Q1 2005) related to ongoing legal proceedings and governmental investigations.

How are Bristol-Myers Squibb's key products performing, and what are the major risks associated with them?

Sales performance is mixed. PLAVIX* continues to show strong growth (+17%), but PRAVACHOL sales declined significantly (-23%) due to competition and exclusivity losses. Newer products like ABILIFY*, REYATAZ, and ERBITUX* are showing robust growth, indicating pipeline success. A major risk highlighted is the ongoing patent litigation surrounding PLAVIX*, where an adverse outcome could lead to significant generic competition and material financial impact.

What is the company's outlook regarding ongoing legal matters and their potential financial impact?

Bristol-Myers Squibb acknowledges numerous significant pending lawsuits, claims, proceedings, and investigations. Management states that it is not currently possible to assess the final outcome of these matters, but believes the aggregate impact, beyond current reserves, is reasonably likely to be material to the company's results of operations, cash flows, financial condition, and liquidity. This remains a key risk factor for investors.

How is the company managing its international cash and tax liabilities related to the American Jobs Creation Act?

The company repatriated approximately $6.2 billion in special dividends from foreign subsidiaries in Q1 2005, part of an anticipated $9 billion repatriation related to the American Jobs Creation Act. A provision for deferred taxes of $575 million was recorded in Q4 2004. The company expects to use these repatriated funds in accordance with U.S. Treasury Department requirements and continues to monitor for any clarifying guidance.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY2005

Summary

Bristol-Myers Squibb Company (BMY) reported a significant decrease in net earnings for the first quarter of 2005 compared to the same period in 2004, primarily due to a large gain on the sale of its Adult Nutritional business in the prior year and increased litigation charges in the current quarter. Net sales also saw a modest decline of 2%, impacted by ongoing exclusivity losses on established products and increased competition, though this was partially offset by favorable foreign exchange rates and growth in key newer products like PLAVIX*, ABILIFY*, REYATAZ, and ERBITUX*. The company continues to invest heavily in research and development, with a 12% increase year-over-year, focusing on its late-stage pipeline and new product launches. However, significant legal proceedings and investigations remain a material risk, with the company acknowledging that the aggregate impact beyond current reserves could be substantial to its financial condition and operations. Investors should closely monitor the outcomes of major patent litigations, particularly concerning PLAVIX*, and the ongoing legal and regulatory investigations.

Key Highlights

1Net sales decreased by 2% to $4.53 billion in Q1 2005 compared to Q1 2004, impacted by product exclusivity losses and competition.
2Net earnings from continuing operations dropped significantly by 44% to $538 million, or $0.27 per diluted share, compared to $961 million, or $0.49 per diluted share, in the prior year, largely due to a gain on sale of business in the prior year and increased litigation charges.
3Research and development expenses increased by 12% to $653 million, reflecting continued investment in the product pipeline.
4Key product sales showed mixed performance: PLAVIX* sales increased 17%, while PRAVACHOL sales decreased 23% due to competition.
5Significant new product contributions were noted for ABILIFY* (+63%), REYATAZ (+99%), and ERBITUX* (+412%), indicating pipeline success.
6The company faces substantial ongoing legal proceedings and investigations, with management stating the aggregate impact could be material to financial results.
7The company repatriated approximately $6.2 billion in special dividends from foreign subsidiaries as part of the American Jobs Creation Act.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2005

Summary

Key Highlights

Frequently Asked Questions